Phase I Study of S-Trans, Trans-Farnesylthiosalicylic Acid (Salirasib), a Novel Oral RAS Inhibitor in Patients With Refractory Hematologic Malignancies

Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2015.02.018
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

A Phase I Study of Intravenous LBH589, a Novel Cinnamic Hydroxamic Acid Analogue Histone Deacetylase Inhibitor, in Patients With Refractory Hematologic Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2006English

Neuroprotective Effect of S-Trans, Trans-Farnesylthiosalicylic Acid via Inhibition of RAS/ERK Pathway for the Treatment of Alzheimer’s Disease

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2019English

Suppression of Lung Cancer Tumor Growth in a Nude Mouse Model by the Ras Inhibitor Salirasib (Farnesylthiosalicylic Acid)

Molecular Cancer Therapeutics
Cancer ResearchOncology
2007English

Phase I Study of Oral Lenalidomide in Patients With Refractory Metastatic Cancer

Journal of Clinical Pharmacology
Pharmacology
2009English

Phase I Study of a Novel Taxane BMS-188797 in Adult Patients With Solid Malignancies

Clinical Cancer Research
Cancer ResearchOncology
2005English

A Phase I Study of Indoximod in Patients With Advanced Malignancies

Oncotarget
Oncology
2016English

Phase 1 Study of Ixazomib, an Investigational Proteasome Inhibitor, in Advanced Non-Hematologic Malignancies

Investigational New Drugs
OncologyPharmacology
2015English

The Ras Inhibitor Farnesylthiosalicylic Acid as a Potential Therapy for Neurofibromatosis Type 1

Clinical Cancer Research
Cancer ResearchOncology
2006English

Efficacy and Safety of the Dual SYK/JAK Inhibitor Cerdulatinib in Patients With Relapsed or Refractory B-Cell Malignancies: Results of a Phase I Study

American Journal of Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy